investorideas.comSEP 291 min read$LFCR

Lifecore Biomedical (Nasdaq: LFCR) Closes up on Acquisition News

Lifecore Biomedical (LFCR) closed at $6.52, up 55.24%, after announcing a $663.7M acquisition by Webster Equity Partners. Shareholders will receive $6.28 per share in cash plus contingent value rights (CVRs) worth up to $9.67 per share, a 49.5% premium. The deal aims to support Lifecore's growth objectives.

Original reporting

investorideas.com

Published Sep 29, 2026, 6:42 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 29, 2026, 12:19 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Lifecore Biomedical (Nasdaq: LFCR) Closes up on Acquisition News — source image — Source · investorideas.com

Decision brief

The 30-second read

$LFCRBullishHigh

Why it matters

The acquisition by Webster Equity Partners provides immediate cash value and upside via CVRs, likely sustaining the recent price rally.

Market read

The deal sets a new valuation for LFCR and may influence valuation multiples for similar biotech CDMOs.

What to watch

The contingent value rights (CVRs) depend on performance milestones; failure to meet them could reduce total consideration.

Relevance 9/10Novelty 9/10Timing: pre-market today

Background

Lifecore Biomedical (LFCR) is a Nasdaq-listed CDMO focused on biotech and medical technology manufacturing.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$LFCRBullishHigh confidence

Context

LFCR announced a definitive agreement to be acquired by Webster Equity Partners for $6.28 cash per share plus CVRs, driving a 55% price surge.

Expected impact

upward pressure as the market prices in the cash premium and potential CVR upside

Evidence & confidence

Deal terms include a 49.5% cash premium and up to 130% total consideration, prompting strong buying interest.

Market effects

Sector

Consolidation in the CDMO biotech space may spur M&A activity among peers.

Regional

Positive for US biotech sector, modest spillover to related contract manufacturing stocks.

Global

Limited to biotech investors; no broad market impact.

Counterpoint

What could challenge this read

Deal risk includes regulatory approval uncertainty and integration challenges; price may correct if milestones are missed.

Key entities

Company
Lifecore Biomedical
Target of the acquisition.
Investment Firm
Webster Equity Partners
Acquirer offering cash and CVRs.

Read at source ← All news

OCT 20

$LFCRMed

Lifecore Biomedical, Inc. entered into an Agreement and Plan of Merger with Lifecore Inc. and Hazel Merger Sub, Inc. On October 16, 2026, the Board of…

LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, on September 27, 2026, Lifecore Biomedical, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Lifecore Inc. and Hazel Merger Sub, Inc. On October 16, 2026, the Board of Directors (the “

SEC EDGAR 8-K1 min

OCT 2

$HRLMedAI 8/10

Deal Dispatch: Hormel Acquires Brakebush, Onsemi buys Synaptics for $5.7 Billion, Leslie’s Pools Bankrupt

Hormel (HRL) acquires Brakebush for $1.06B; Onsemi (ON) to buy Synaptics for $5.7B; Leslie's files for bankruptcy. Valley National (VLY) to acquire Bluevine for $340M. Yext (YEXT) to acquire Flamel.ai. Lifecore (LFCR) to be acquired by Webster Equity for up to $663.7M. SoftBank completes DigitalBridge acquisition. GBTG acquired by Long Lake for $6.3B.

benzinga.com3 min

SEP 28

$LFCRHighAI 9/10

Lifecore Agrees To $663.7 Million Buyout Deal With Webster Equity Partners; Stock Up

Lifecore Biomedical (LFCR) agreed to a $663.7M buyout by Webster Equity Partners at $6.28 per share, a 49.5% premium. Shareholders may receive additional payments if performance milestones are met. The deal, approved by the board, is expected to close by Q4 2026. LFCR shares rose 56.79% to $6.59.

rttnews.com2 min

SEP 28

$LFCRHighAI 9/10

Lifecore Biomedical To Be Taken Private By Webster Equity Partners In Up To $663.7 Mln Deal

Lifecore Biomedical (LFCR) agreed to be acquired by Webster Equity Partners for up to $663.7 million. The deal offers $6.28 per share plus a CVR, representing a 49.5% premium. The transaction, expected to close in Q4 2026, requires shareholder and regulatory approvals. Lifecore's stock will be delisted post-closing.

rttnews.com2 min

AUG 12

$LFCRMedAI 8/10

Lifecore Biomedical (LFCR) Q2 2026 Earnings Call Transcript

Lifecore Biomedical (LFCR) reported Q2 2026 revenue of $34.2M, down 6.2% year over year, and a net loss of $6.2M ($0.19/share). Adjusted EBITDA was $8.6M. Gross margin fell to 35.3%. The company reaffirmed 2026 revenue guidance of $120M to $125M and adjusted EBITDA guidance of $20.5M to $25M, citing a 2027 demand inflection tied to Japanese market approval.

fool.com6 min

AUG 5